Amneal Recalls Extended Phenytoin Sodium Capsules Due to Dissolution Failure
Amneal Pharmaceuticals is recalling Extended Phenytoin Sodium Capsules because they failed to meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Amneal Pharmaceuticals of New York, LLC. is recalling Extended Phenytoin Sodium Capsules, USP, 100 mg. The recall is limited to bottles containing 895 to 1,000 capsules with NDC 65162-212-11, Batch/Lot HL50611, and an expiration date of 1/2014.
The recall was initiated because the product failed to meet dissolution specifications. This means the capsules may not release the medication in the body as intended, potentially affecting the drug's efficacy.
The affected product was distributed in Illinois, New Hampshire, New Jersey, New York, Ohio, Rhode Island, and Tennessee. Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for a replacement or further instructions.
The recalled product
- Product
- EXTENDED PHENYTOIN SODIUM (PHENYTOIN SODIUM)
- Brand
- EXTENDED PHENYTOIN SODIUM
- Manufacturer
- Amneal Pharmaceuticals of New York, LLC.
- Category
- Drug — Anticonvulsant
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Batch/Lot HL50611
- exp. 1/2014
UPCs (2)
- 0365162212037
- 0365162212105
Distribution
Related recalls
Same brand · EXTENDED PHENYTOIN SODIUM
- HighPrescription Drug Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2023-11-15
- HighPrescription Drug Recall: Extended Phenytoin Sodium Dissolution Failure
FDA (Drugs) · 2023-06-21
Same manufacturer · Amneal Pharmaceuticals of New York, LLC.
See all →- HighMethylergonovine Maleate tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-05-08
- SevereVancomycin Hydrochloride Oral Solution Recalled Nationwide for Superpotency Due to Overfilling
FDA (Drugs) · 2024-04-24
- HighDivalproex Sodium 250 mg tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-04-03
- ModerateFDA Recalls Oseltamivir Phosphate Oral Suspension for Out-of-Specification Impurities
FDA (Drugs) · 2024-02-28
- HighAmneal Phenoxybenzamine Hydrochloride Capsules 10mg Recalled Due to Unknown Impurity
FDA (Drugs) · 2024-02-14
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17